These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 20726794)

  • 1. A mathematical model for peptide inhibitor design.
    Pang X; Zhou L; Zhang M; Xie F; Yu L; Zhang L; Xu L; Zhang X
    J Comput Biol; 2010 Aug; 17(8):1081-93. PubMed ID: 20726794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategy for discovering chemical inhibitors of human cyclophilin a: focused library design, virtual screening, chemical synthesis and bioassay.
    Li J; Zhang J; Chen J; Luo X; Zhu W; Shen J; Liu H; Shen X; Jiang H
    J Comb Chem; 2006; 8(3):326-37. PubMed ID: 16677001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, structural analysis and biochemical studies of stapled AIF(370-394) analogues as ligand of CypA.
    Monti A; Sturlese M; Caporale A; Roger JA; Mascanzoni F; Ruvo M; Doti N
    Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129717. PubMed ID: 32861757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational full electron structure study of biological activity in Cyclophilin A.
    Zhou W; Rossetto AM; Pang X; Zhou L
    J Biomol Struct Dyn; 2016; 34(4):870-6. PubMed ID: 26264861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro.
    Pang X; Zhang M; Zhou L; Xie F; Lu H; He W; Jiang S; Yu L; Zhang X
    Eur J Med Chem; 2011 May; 46(5):1701-5. PubMed ID: 21396746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophilin A inhibition: targeting transition-state-bound enzyme conformations for structure-based drug design.
    Nagaraju M; McGowan LC; Hamelberg D
    J Chem Inf Model; 2013 Feb; 53(2):403-10. PubMed ID: 23312027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation.
    Seizer P; Schönberger T; Schött M; Lang MR; Langer HF; Bigalke B; Krämer BF; Borst O; Daub K; Heidenreich O; Schmidt R; Lindemann S; Herouy Y; Gawaz M; May AE
    Atherosclerosis; 2010 Mar; 209(1):51-7. PubMed ID: 19758589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The full electron structure of the FKBP12/FK506 complex.
    Rossetto AM; Zhou W; Pang X; Zhou L
    J Biomol Struct Dyn; 2015; 33(2):388-94. PubMed ID: 24471694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of small molecule binding molecules by affinity purification using a specific ligand immobilized on PEGA resin.
    Kuramochi K; Miyano Y; Enomoto Y; Takeuchi R; Ishi K; Takakusagi Y; Saitoh T; Fukudome K; Manita D; Takeda Y; Kobayashi S; Sakaguchi K; Sugawara F
    Bioconjug Chem; 2008 Dec; 19(12):2417-26. PubMed ID: 19035789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rough set-based proteochemometrics modeling of G-protein-coupled receptor-ligand interactions.
    Strömbergsson H; Prusis P; Midelfart H; Lapinsh M; Wikberg JE; Komorowski J
    Proteins; 2006 Apr; 63(1):24-34. PubMed ID: 16435365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical force field parameters for two high-affinity ligands of FKBP12.
    Olivieri L; Gardebien F
    J Mol Graph Model; 2014 Apr; 49():118-28. PubMed ID: 24657432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the binding sites for the interactions between FKBP12 and intracellular calcium release channels.
    Wen H; Kang S; Song Y; Song Y; Yang HJ; Kim MH; Park S
    Arch Biochem Biophys; 2012 Jan; 517(1):37-42. PubMed ID: 22100703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a New class of nanomolar FKBP12 ligands.
    Martina MR; Tenori E; Bizzarri M; Menichetti S; Caminati G; Procacci P
    J Med Chem; 2013 Feb; 56(3):1041-51. PubMed ID: 23301792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pose scoring by NMR.
    Wang B; Raha K; Merz KM
    J Am Chem Soc; 2004 Sep; 126(37):11430-1. PubMed ID: 15366876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On-chip fragment-based approach for discovery of high-affinity bivalent inhibitors.
    Miyazaki I; Simizu S; Ishida K; Osada H
    Chembiochem; 2009 Mar; 10(5):838-43. PubMed ID: 19226504
    [No Abstract]   [Full Text] [Related]  

  • 16. Preparation, characterization and refolding in vitro of a recombinant human cyclophilin A mutant: effect of a single Pro/Ser substitution on cyclophilin A structure and properties.
    Xu LR; Yan X; Luo M; Guan YX; Yao SJ
    Biotechnol Prog; 2008; 24(2):302-10. PubMed ID: 18333624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A library of fluorescent peptides for exploring the substrate specificities of prolyl isomerases.
    Zoldák G; Aumüller T; Lücke C; Hritz J; Oostenbrink C; Fischer G; Schmid FX
    Biochemistry; 2009 Nov; 48(43):10423-36. PubMed ID: 19785464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural characterization of the RyR1-FKBP12 interaction.
    Samsó M; Shen X; Allen PD
    J Mol Biol; 2006 Mar; 356(4):917-27. PubMed ID: 16405911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptidyl-prolyl isomerase activity of FK506 binding protein 12 prevents tau peptide from aggregating.
    Ikura T; Ito N
    Protein Eng Des Sel; 2013 Sep; 26(9):539-46. PubMed ID: 23832849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Novel Extracellular Cyclophilin A (CyPA) - Inhibitor MM284 Reduces Myocardial Inflammation and Remodeling in a Mouse Model of Troponin I -Induced Myocarditis.
    Heinzmann D; Bangert A; Müller AM; von Ungern-Sternberg SN; Emschermann F; Schönberger T; Chatterjee M; Mack AF; Klingel K; Kandolf R; Malesevic M; Borst O; Gawaz M; Langer HF; Katus H; Fischer G; May AE; Kaya Z; Seizer P
    PLoS One; 2015; 10(4):e0124606. PubMed ID: 25894208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.